Results 171 to 180 of about 31,032 (201)

Letrozole

Reactions Weekly, 2022
openaire   +1 more source

Letrozole

Reactions Weekly, 2018
  +4 more sources

Letrozole

Reactions Weekly, 2014
  +4 more sources

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Lancet Oncology, The, 2020
Aleix Prat, Cristina Saura, Laia Paré
exaly  

Letrozole

Reactions Weekly, 2011
openaire   +1 more source

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Lancet Oncology, The, 2015
, Johannes Ettl, Marcus Schmidt
exaly  

Palbociclib and Letrozole in Advanced Breast Cancer

New England Journal of Medicine, 2016
Richard S Finn, Miguel Martin, Hope S Rugo   +2 more
exaly  

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Journal of Clinical Oncology, 2007
Alan S Coates, Aparna Keshaviah, John F Forbes   +2 more
exaly  

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncology, The, 2019
Eleftherios P Mamounas, Jong-Hyeon Jeong, Adam M Brufsky   +2 more
exaly  

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

Journal of Clinical Oncology, 2001
Justus Apffelstaedt
exaly